Diag Capital Management’s AbbVie ABBV Stock Holding History

Diag Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$4.65M	Buy	+50,420	New	+$4.43M	5.32%	4

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Diag Capital Management's ABBV Position: Q4 2018 in Review

Diag Capital Management opened a new position in AbbVie (ABBV) in Q4 2018: 50,420 shares worth $4.65M. The stake represents 5.32% of the portfolio and ranks #4 among its holdings.

2,063 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

Diag Capital Management held 50,420 shares of AbbVie worth $4.65M as of Q4 2018.
AbbVie was a new Diag Capital Management position in Q4 2018.
AbbVie made up 5.32% of Diag Capital Management's portfolio in Q4 2018, its #4 holding.
2,063 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.